What is Stone Man Syndrome (FOP)?

The Hook

Fibrodysplasia ossificans progressiva (FOP), nicknamed “stone man syndrome,” is a disease where the body slowly builds a second skeleton — turning muscle, tendon, and ligament into real bone. The strangest part is that almost all of it traces back to one tiny typo in a single gene.

The Science

Your cells carry molecular “switches” on their surface called receptors that tell them what to do. One of them, made by a gene called ACVR1 (also known as ALK2), helps decide when connective-tissue cells should build bone.

In FOP, a single-letter mutation in ACVR1 jams that switch. Two things go wrong: the receptor sits partly stuck in the “on” position, and — the key discovery — it now misreads a molecule called Activin A. In a healthy body, Activin A tells this receptor to stay quiet. In FOP, that “stop” signal gets read as “go.”

Here’s why that’s devastating: Activin A floods to any site of injury or inflammation — a bruise, a fall, even a muscle strain. So instead of healing the soft tissue, the body lays down organized bone across it, often locking joints in place. Two more hallmarks: babies with FOP are almost always born with malformed big toes, and trying to cut the extra bone out only triggers more of it to grow.

The new bone isn’t a random lump, either — it’s real, organized bone, with its own marrow, that connects into the existing skeleton. The process tends to follow a predictable pattern over a person’s life, generally moving from the neck and shoulders downward and from the body’s center outward toward the limbs. Flare-ups often begin as painful, swollen soft-tissue lumps that can be mistaken for tumors before they harden.

Because ordinary bumps and even routine medical procedures can set off this bone growth, everyday events that would heal in anyone else can instead trigger a flare. This is why the malformed big toe at birth matters so much: it can let doctors recognize FOP early, before a well-meant biopsy or injection accidentally provokes new bone.

Three Wild Facts

• The mutation behind classic FOP is astonishingly consistent — the same single letter of the ACVR1 gene is changed in the vast majority of people worldwide, which is rare for a genetic disease.
• FOP is thought to affect only about 1 in 1–2 million people, making it one of the rarest conditions known to medicine.
• Because injury triggers new bone, standard fixes backfire: intramuscular injections and surgery to remove the bone can each spark fresh growth — so for years, care could only focus on prevention and protection. That has finally changed: the first FOP-specific drugs are now FDA-approved.

Why It Matters

FOP is extraordinarily rare — roughly one in a million to two million people — but it’s a stark lesson in how much a single signal can control. It also flips normal intuition about medicine: for most conditions you’d operate to remove the problem, but here surgery makes it worse. And understanding the Activin A trigger is exactly why the treatment story has now caught up with the science. Two drugs are FDA-approved for FOP, and they work in different ways. The first, palovarotene (Sohonos) — approved in 2023 as the first FOP-specific therapy — is a retinoic-acid-receptor drug that dampens the pathway laying down the extra bone; it does not touch Activin A. The second, garetosmab (Pasatru), approved in August 2026, does exactly what the biology predicts: it’s an antibody that blocks Activin A itself, the misread signal at the heart of the disease. It’s a case where decoding one broken switch pointed straight at the treatment — and the treatment arrived.